These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 17884399)

  • 1. Grafting of abciximab to a microbubble-based ultrasound contrast agent for targeting to platelets expressing GP IIb/IIIa - characterization and in vitro testing.
    Della Martina A; Allémann E; Bettinger T; Bussat P; Lassus A; Pochon S; Schneider M
    Eur J Pharm Biopharm; 2008 Mar; 68(3):555-64. PubMed ID: 17884399
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incomplete inhibition of platelet aggregation and glycoprotein IIb-IIIa receptor blockade by abciximab: importance of internal pool of glycoprotein IIb-IIIa receptors.
    Gawaz M; Ruf A; Pogatsa-Murray G; Dickfeld T; Rüdiger S; Taubitz W; Fischer J; Müller I; Meier D; Patscheke H; Schömig A
    Thromb Haemost; 2000 Jun; 83(6):915-22. PubMed ID: 10896249
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Augmentation of inhibitory effects of glycoprotein IIb-IIIa antagonists in patients with diabetes.
    Keating FK; Whitaker DA; Sobel BE; Schneider DJ
    Thromb Res; 2004; 113(1):27-34. PubMed ID: 15081562
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro measurement of platelet glycoprotein IIb/IIIa receptor blockade by abciximab: interindividual variation and increased platelet secretion.
    Rossi F; Rossi E; Pareti FI; Colli S; Tremoli E; Gallo L
    Haematologica; 2001 Feb; 86(2):192-8. PubMed ID: 11224490
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The GP IIb/IIIa inhibitor abciximab (ReoPro) decreases activation and interaction of platelets and leukocytes during in vitro cardiopulmonary bypass simulation.
    Straub A; Wendel HP; Azevedo R; Ziemer G
    Eur J Cardiothorac Surg; 2005 Apr; 27(4):617-21. PubMed ID: 15784360
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Upregulation of GP IIb/IIIa receptors during platelet activation: influence on efficacy of receptor blockade.
    Matzdorff A; Voss R
    Thromb Res; 2006; 117(3):307-14. PubMed ID: 15894353
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Occupancy of the internal and external pools of glycoprotein IIb/IIIa following abciximab bolus and infusion.
    Quinn MJ; Murphy RT; Dooley M; Foley JB; Fitzgerald DJ
    J Pharmacol Exp Ther; 2001 May; 297(2):496-500. PubMed ID: 11303035
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Paradoxical platelet activation was not observed on dissociation of abciximab from GpIIb-IIIa complexes.
    Ndoko S; Poujol C; Combrié R; Nurden A; Nurden P
    Thromb Haemost; 2002 Feb; 87(2):317-22. PubMed ID: 11858493
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Combination therapy for acute myocardial infarction with glycoprotein IIb/IIIa inhibitors and fibrinolysis].
    Ottani F; Bresciani B; La Vecchia L; Favero L; Fontanelli A; Galvani M
    Ital Heart J Suppl; 2002 May; 3(5):544-54. PubMed ID: 12064194
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of glycoprotein IIb-IIIa receptor antagonism on platelet membrane glycoproteins after coronary stent placement.
    Gawaz M; Ruf A; Neumann FJ; Pogátsa-Murray G; Dickfeld T; Zohlnhöfer D; Schömig A
    Thromb Haemost; 1998 Dec; 80(6):994-1001. PubMed ID: 9869173
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantification of abciximab-induced platelet inhibition is assay dependent: a comparative study in patients undergoing percutaneous coronary intervention.
    Furman MI; Kereiakes DJ; Krueger LA; Mueller MN; Broderick TM; Schneider JF; Howard WL; Fox ML; Barnard MR; Frelinger AL; Michelson AD
    Am Heart J; 2003 Feb; 145(2):e6. PubMed ID: 12595861
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of glycoprotein IIb/IIIa antagonist abciximab on monocyte-platelet aggregates and tissue factor expression.
    Steiner S; Seidinger D; Huber K; Kaun C; Minar E; Kopp CW
    Arterioscler Thromb Vasc Biol; 2003 Sep; 23(9):1697-702. PubMed ID: 12869353
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Free and total platelet glycoprotein IIb/IIIa measurement in whole blood by quantitative flow cytometry during and after infusion of c7E3 Fab in patients undergoing PTCA.
    Hézard N; Metz D; Nazeyrollas P; Nguyen P; Simon G; Daliphard S; Droullé C; Elaerts J; Potron G
    Thromb Haemost; 1999 Jun; 81(6):869-73. PubMed ID: 10404759
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of glycoprotein IIb/IIIa inhibitors on CD62p expression, platelet aggregates, and microparticles in vitro.
    Matzdorff AC; Kühnel G; Kemkes-Matthes B; Pralle H; Voss R; Fareed J
    J Lab Clin Med; 2000 Mar; 135(3):247-55. PubMed ID: 10711863
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Binding of abciximab to alpha V beta 3 and activated alpha M beta 2 receptors: with a review of platelet-leukocyte interactions.
    Coller BS
    Thromb Haemost; 1999 Aug; 82(2):326-36. PubMed ID: 10605721
    [No Abstract]   [Full Text] [Related]  

  • 16. In vivo ultrasound molecular imaging of inflammatory thrombosis in arteries with cyclic Arg-Gly-Asp-modified microbubbles targeted to glycoprotein IIb/IIIa.
    Wu W; Wang Y; Shen S; Wu J; Guo S; Su L; Hou F; Wang Z; Liao Y; Bin J
    Invest Radiol; 2013 Nov; 48(11):803-12. PubMed ID: 23857134
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of GP IIb/IIIa inhibitors on vascular inflammation, coronary microcirculation, and platelet function.
    Kereiakes DJ
    Rev Cardiovasc Med; 2006; 7 Suppl 4():S3-11. PubMed ID: 17224889
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An additional mechanism of action of abciximab: dispersal of newly formed platelet aggregates.
    Marciniak SJ; Mascelli MA; Furman MI; Michelson AD; Jakubowski JA; Jordan RE; Marchese PJ; Frelinger AL
    Thromb Haemost; 2002 Jun; 87(6):1020-5. PubMed ID: 12083481
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular imaging of human thrombus with novel abciximab immunobubbles and ultrasound.
    Alonso A; Della Martina A; Stroick M; Fatar M; Griebe M; Pochon S; Schneider M; Hennerici M; Allémann E; Meairs S
    Stroke; 2007 May; 38(5):1508-14. PubMed ID: 17379828
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glycoprotein IIb/IIIa and P2Y12 receptor antagonists yield additive inhibition of platelet aggregation, granule secretion, soluble CD40L release and procoagulant responses.
    Judge HM; Buckland RJ; Holgate CE; Storey RF
    Platelets; 2005 Nov; 16(7):398-407. PubMed ID: 16236601
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.